Fresenius SE & Co KGaA (FRE)
Industry Medical Care Facilities
This stock can be held in an Investment ISA and an Investment Account
Sell
€47.52
Buy
€47.53
€-1.07 (-2.21%)
Prices updated at 16 Dec 2025, 16:35 CET
| Prices minimum 15 mins delay
Prices in EUR
Fresenius SE & Co KGaA is a holding company engaged in healthcare business. It provides dialysis machines, and manufactures equipment for Medical Care through its subsidiaries. The company also manufactures IV drugs, clinical nutrition, and infusion.
-0.47%
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 21,067m | 21,833m | |
| 4,971m | 5,378m | |
| 1,183m | 1,782m | |
| 5.62 | 8.16 | |
| -594m | 471m | |
| 2,692m | 3,139m | |
| Sales, General and administrative | 3,027m | 2,919m |
| Interest expenses | 519m | 547m |
| Provision for income taxes | 485m | 521m |
| Operating expenses | 3,788m | 3,596m |
| Income before taxes | 773m | 1,388m |
| Net income available to common shareholders | -594m | 471m |
| -1.05 | 0.84 | |
| Net interest income | -398m | -432m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.05 | 0.84 |
| Free cash flow per share | 3.9557 | 4.0853 |
| Book value/share | 35.5694 | 33.4264 |
| Debt equity ratio | 0.697352 | 0.552912 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 12,520m | 11,446m |
| Current liabilities | 9,330m | 9,009m |
| Total capital | 30,456m | 29,019m |
| Total debt | 15,830m | 13,577m |
| Total equity | 18,999m | 19,542m |
| Total non current liabilities | - | - |
| Loans | 11,457m | 9,477m |
| Total assets | 45,284m | 43,550m |
| Total liabilities | - | - |
| Cash and cash equivalents | 2,289m | 2,046m |
| Common stock | 563m | 563m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 2,749m | 2,562m |
| Cash dividends paid | -550m | - |
| 3,322m | 1,524m | |
| Investments (gains) losses | -3,187m | -510m |
| 2,562m | 2,282m | |
| Net income | - | - |
| 4,456m | 2,447m | |
| -1,134m | -923m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.